Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ANDRX (ADRX) -- Ignore unavailable to you. Want to Upgrade?

To: PAUL ROBERT ST. ONGE who wrote (67)	4/26/1998 5:52:00 PM
From: Jolie Renee	Read Replies (1) \| Respond to of 127

Pasting here the Yahoo post that spoke more about this article: --------------------------------------------------- Message 367 of 367 Good article, thanks Paul! keithpack Apr 26 1998 1:56PM EDT A key portions of the article you mentioned was... "Their ability to develop generic, controlled release drugs is very good," said analyst Jerry Treppel of SBC Warburg Dillon Read Inc. "They've developed a good track record...and their distribution business is going gangbusters." According to this analyst, 95% of 1997 sales came from this distribution business with a customer base of over 8,000 clients.